Spruce Street Capital LP Takes $12.26 Million Position in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 297,437 shares of the company’s stock, valued at approximately $12,257,000. Dianthus Therapeutics comprises about 4.0% of Spruce Street Capital LP’s portfolio, making the stock its 10th largest holding. Spruce Street Capital LP owned about 0.69% of Dianthus Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $40,000. Deutsche Bank AG increased its position in shares of Dianthus Therapeutics by 9.3% during the fourth quarter. Deutsche Bank AG now owns 15,831 shares of the company’s stock valued at $652,000 after buying an additional 1,343 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at about $27,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics during the third quarter valued at about $64,000. 47.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DNTH has been the topic of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a research report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target on the stock. Oppenheimer boosted their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $82.51 on Tuesday. The stock has a market cap of $4.51 billion, a PE ratio of -19.98 and a beta of 1.18. Dianthus Therapeutics, Inc. has a fifty-two week low of $16.64 and a fifty-two week high of $96.50. The firm’s 50-day simple moving average is $87.03 and its two-hundred day simple moving average is $65.49.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ryan Savitz sold 8,224 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the completion of the sale, the executive vice president owned 8,224 shares in the company, valued at approximately $738,844.16. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 149,121 shares of company stock worth $12,635,454. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.